BSH 2017 | CheckMate study and the role of nivolumab in Hodgkin lymphoma
Christopher Fox, MBChB, MRCP, FRCPath, from Nottingham University Hospital, Nottingham, UK discusses the CheckMate study at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. The CheckMate study (NCT03138499), investigated the role of nivolumab in patients with classical Hodgkin lymphoma, who had failed autologous stem cell transplant, and had not been exposed to brentuximab vedotin, compared to the other group, who had higher response rates, and went on to have allogeneic transplants and durable remission. He states that the use of checkpoint inhibitors to treat Hodgkin lymphoma is a big step forward. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
